anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The nine orthodontic patients will receive 36 orthodontic molar tubes coated with ZnO nanoparticle in split-mouth cross quadrant manner, In each patient, two diagonal quadrants (i.e., upper right and lower left, or vice versa) will randomly assigned to each coated OMT and UOMT groups. evaluation will be after 2 weeks for microbial assessment biofilm in addition to plaque \& gingival index. patients will be follow up for 3 month to evaluation bond failure rate.
The incidence of short-term insomnia is high. In clinical practice, due to patients insufficient understanding of the severity of short-term insomnia and the side effects of drug treatment, the treatment of short-term insomnia has not made breakthrough progress, and some patients may turn into chronic insomnia, which is more harmful. There is a growing consensus that short-term insomnia is a hyperarousal disorder associated with high sleep reactivity. "Chou's Tiaoshen" acupoints is derived from the experience of Zhou Dean, a national famous traditional Chinese medicine doctor in our department, and the main points are selected: Baihui (DU20), Shenting (DU24), Sishencong (EX-HN1), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6), the acupuncture method has achieved good clinical efficacy in the early insomnia research, which can improve the waking state of insomnia patients during the day and improve the sleep quality at night. In order to further verify the efficacy of "Chou's Tiaoshen" acupoints in the treatment of short-term insomnia, explore the possible mechanism of action, discover the physical characteristics of patients with short-term insomnia, and explain the connotation of "Chou's Tiaoshen" acupoints, this clinical study is conducted. 96 patients with short-term insomnia who meet the inclusion criteria will be selected and divided into the "Chou's Tiaoshen" acupoints group and the oral esazolam group according to the principle of random allocation. The study will be conducted in the acupuncture and moxibustion Department of Beijing Hospital of Traditional Chinese Medicine and Shunyi Hospital of Beijing Hospital of Traditional Chinese Medicine. Pittsburgh Sleep Scale (PSQI) assessment, polysomnography (PSG, some subjects), heart rate variability (HRV) monitoring, serum cortisol measurement will be performed before and after treatment. Ford Insomnia Stress Response Test (FIRST) scale, Daytime function Scale and Chinese Medicine Symptom Score Scale will be evaluated to evaluate the efficacy and explore the mechanism.
Participants in this group received probiotic iNatal® (Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactococcus lactis SP38, Lacticaseibacillus casei R0215) - dosage 1 sachet per day, during the 24-36 weeks of their gestation period.
Sea bass,  Dicentrarchus labrax,  is one of the most cultivated species in the EU. A problem related to the cultivation thereof is the early onset of puberty which leads to poor growth and deterioration in the quality of the meat. The invention pertains to the sector of biotechnology (sector of application of aquaculture). The invention relates to the cloning strategy of the gonadotropin-inhibitory hormone (GnIH) of sea bass, which contains two new peptides of the RFamide family. These peptides have been synthesised and used to generate specific antibodies and have exhibited inhibitory effects on different neuroendocrine and endocrine factors which control the reproduction of sea bass. This invention can be useful for controlling the puberty, reproduction, ingestion and growth of fish.
PURPOSE: A composition containing pedicel extract of cherry tomato for preventing or treating atopic dermatitis is provided to remove keratinocyte toxicity and to ensure antibacterial activity. CONSTITUTION: A composition for preventing and treating atopic dermatitis contains pedicel extract of cherry tomato as an active ingredient. The mixture ratio of alcohol solution and water is 1-99(v/v)%. A functional cosmetic product contains the composition for preventing and treating atopic dermatitis as an active ingredient. The cosmetic product is used in the form of toner, nutrition lotion, nutrition essence, massage cream, or foaming formulation. The extract is prepared by adding 1-30 weight parts of alcohol solution of 1-10 carbon atoms and extracting at 40-110 °C for 1-10 hours.
NEW MATERIAL:A functional protein obtained by linking activated branched polysaccharides to a protein. EXAMPLE:An egg white albumin-dextran conjugate. USE:An emulsifying agent for foods and cosmetics. PREPARATION:For example, polysaccharides (e.g., dextran) are dissolved in water and an aqueous solution of caustic soda is added thereto while stirring the solution to adjust the pH to 10.7. Cyanogen bromide is then dripped while stirring the resultant adjusted solution and reaction is carried out by keeping the pH in the reaction system at 10.7 to afford activated polysaccharides. The obtained polysaccharides are then dialyzed against an aqueous solution of sodium carbonate at pH9.0 and an aqueous solution of a protein (e.g., egg white albumin) is added thereto while keeping the pH in the system at 9.0 to carry out coupling reaction at 4 deg.C for 12hr. Thereby, the aimed functional protein consisting of a conjugate of the branched polysaccharides with the protein is obtained.
The present disclosure relates to an apparatus, method, and device-readable medium for determining a risk of a user. An apparatus for determining a risk of a user using multiple data types is disclosed. The system, method and program product also perform the functions of the apparatus. The means for determining a risk of the user using the plurality of data types includes a processor and a memory. The memory stores code executable by the processor. The processor receives first data about the user and determines a first probability that the user is at risk using the first data. In response to the first probability exceeding a first threshold, the processor receives second data, the second data being a different type of data than the first data. The processor also determines a second probability that the user is at risk using the second data. Responsive to the second probability exceeding a second threshold, the processor initiates an alert.
For postoperative analgesia, all patients (including Rhomboid block and Erector spinae block) will be administered 100 mg tramadol and 1 gr paracetamol. No additional intervention other than this medical approach will be applied in the control group.
BACKGROUND: Pediatric myelodysplastic syndromes (MDS) are rare disorders with an unrevealed pathogenesis. Our aim is to explore the role of genetic factors in the pathogenesis of MDS in children with different outcomes and to discover the correlation between genetic features and clinical outcomes as well as disease characteristics.
METHODS: We conducted an analysis of archived genetic data from 26 patients diagnosed with pediatric MDS at our institution between 2015 and 2021, examining the association between different genetic characteristics and clinical manifestations as well as prognosis. Additionally, We presented three cases with distinct genetic background and outcomes as examples to elaborate the role of genetic factors in pediatric MDS with different prognoses.
RESULTS: Genetic variations were detected in 13 out of the 26 patients, including 8 patients with co-occurrence of somatic and germline mutations (CSGMs) and 5 patients with somatic mutations alone. Our analysis revealed that advanced MDS (4/8, 50% vs. 1/5, 20% and 4/11, 36.4%), PD (3/8, 37.5% vs. 1/5, 20% and 1/11 9.1%), and TD (6/8, 75% vs. 2/5, 40% and 2/11, 18.2%) were more common in patients with CSGMs than those with somatic mutations alone or without any mutations. We also found out in our study that 8 patients with CSGMs had evidently different clinical outcomes, and we presented 3 of them as examples for elaboration. Case 1 with germline and somatic mutations of unknown significance had a relatively slow disease course and a good prognosis. Case 2 with compound heterozygous germline SBDS variants and somatic mutations like del20q had a stable disease course and a reversed outcome. Case 3 with a germline GATA2 variant and somatic mutations including - 7 had a rapidly progressive disease course and a worst prognosis.
CONCLUSION: Our findings indicate that genetic background of pediatric MDS is closely linked with disease characteristics as well as outcomes and that CSGMs may lead to disease progression. It should be emphasized that the interaction between certain germline variants and somatic mutations, such as SBDS and del20q, may result in hematopoietic stem cell adaptation (improved hematopoiesis) and reversed clinical outcomes, which can facilitate the development of targeted therapy.
All patients have been diagnosed with COVID-19. The purpose of this study is to look at this group of patients in the potential to develop Aspergillosis and other fungal infections.
Aliskiren: Do not co-administer aliskiren with MICARDIS in patients with diabetes. Avoid use of aliskiren with MICARDIS in patients with renal impairment (GFR <60 mL/min).

Digoxin: When MICARDIS was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Therefore, monitor digoxin levels when initiating, adjusting, and discontinuing telmisartan for the purpose of keeping the digoxin level within the therapeutic range.

Lithium: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists including MICARDIS. Therefore, monitor serum lithium levels during concomitant use.

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.

The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.
The invention relates to a polypeptide capable of binding to human CD47 protein, which comprises 3 complementarity determining regions CDR1-3, wherein the sequence of CDR1 is or comprises one of the sequences shown in SEQ ID NO. 1-13, the sequence of CDR2 is or comprises one of the sequences shown in SEQ ID NO. 14-24, and the sequence of CDR3 is or comprises one of the sequences shown in SEQ ID NO. 25-34. Aiming at a tumor immunotherapy target of CD47, a nano antibody VHH specifically combined with CD47 is screened by preparing a CD47 protein, immunizing alpaca, utilizing a platform technology of phage library display nano monoclonal antibody and the like, and a humanized antibody is constructed; and simultaneously, identifying the binding of the humanized antibody and the cell surface CD47 protein by using a flow cytometry detection method. The invention provides a potential nano antibody new drug for clinical treatment of various cancers.
This is a single-center, prospective, randomized study to evaluate clinical utility of TruGraf testing in patients with the following characteristics:1.Stable serum creatinine: current serum creatinine \<2.3 mg/dl, \<20% increase compare to the average of the previous 3 serum creatinine levels2.Kidney transplant patients who are:•more than 60 days post-transplant will be included in this study (Study A) •more than 2-yearspost-transplant but less than 5 years post-transplant (\>24 months but \< 60 months) will be included in this study (Study B) Scripps will enroll subjects who are post-transplant and are undergoing routine management. In Study A, patients will receive testing eight times: Month 2 (at time of surveillance biopsy) 6(at time of surveillance biopsy), 9, 12(at time of surveillance biopsy), 15, 18, 21 and 24(at time of surveillance biopsy) (plus or minus two weeks). Results of the genomic analysis will be considered in determining patient treatment plans and as a molecular guide to perform a surveillance biopsy. Clinical data elements using the Scripps EHR and cost of care will be collected for all subjects. In Study B, patients who are at least 2 years post transplant up to 5 years post-transplant will receive testing 8 times: Months 3 ,6, 9, 12, 15, 18, 21 and 24 (plus or minus two weeks)from the time of enrollment into the study. Results of the genomic analysis will be considered in determining patient treatment plans and whether any change is needed, such as whether to perform a surveillance biopsy. Clinical data elements using the Scripps EHR and cost of care will be collected for all subjects. We expect Study A to be completed 24-30months and Study B to be completed in 24-30 months.
<P>PROBLEM TO BE SOLVED: To provide a means for easily supplying insulin to corium or subcutaneous tissue.  <P>SOLUTION: The insulin or an insulin product is contained in a thin needle 2 whose main component material is composed of the mixture of maltose and dextran or trehalose. A part or the whole of the thin needle 2 is inserted to skin for dissolution or residue so as to administer the insulin to a living body. The base material of the thin needle 2 staying in the skin is a saccharide, therefore it is harmless to a human body. A board 1 is also composed of a natural saccharide. Accordingly, the needle is easily and safely abandoned after usage.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
INTRODUCTION: Monitoring, Evaluation and Learning (MEL) is an integral part of research, programme and policy development and implementation. However, MEL methods used to monitor and evaluate interdisciplinary research projects are often informal and under-reported. This article describes the MEL protocol of the UKRI GCRF Action Against Stunting Hub (AASH).
METHODS AND ANALYSIS: The AASH conducts interdisciplinary research into childhood stunting in India, Indonesia and Senegal across 23 distinct work packages. Project-specific MEL framework and methods will be implemented. A logframe will be developed to monitor and evaluate the research activities across the field sites including the number of participants recruited, questionnaires, measurements and procedures completed. MEL dashboards using Tableau and Glasscubes will be used to track and report progress, milestones and outcomes of the project. Dashboard outputs will be reported as numbers and percentages, with additional graphs/charts for easy visualisation. A 'learning' framework will be developed to outline appropriate pipelines for the dissemination of the research findings. This includes a theory of change explicating the overarching ambitions of the project in influencing policy, practice and research, and strategic engagement of relevant stakeholders to evaluate knowledge, attitudes and best practices for impactful engagement and dissemination of the research findings.
ETHICS AND DISSEMINATION: Ethical approval was granted by the Ethics Committee of the London School of Hygiene & Tropical Medicine (17915/RR/17513); National Institute of Nutrition (ICMR)-Ministry of Health and Family Welfare, Government of India (CR/04/I/2021); Health Research Ethics Committee, University of Indonesia and Cipto Mangunkusumo Hospital (KET-887/UN2.F1/ETIK/PPM.00.02/2019); and the National Ethics Committee for Health Research (CNERS), Senegal (Protocole SEN19/78). Findings from this work will be published in peer-reviewed journals, presented in conferences and disseminated to policy makers and research communities.
Background and Objectives: Over the past decade, there has been increasing attention paid to advanced and innovative cardiovascular magnetic resonance (CMR) modalities, such as T1 and T2 mapping, which play a major role in diagnosing diffuse myocardial disease. There is little data summarizing the current evidence regarding the diagnostic accuracy of T1 and T2 mapping, and extracellular volume (ECV) in acute myocarditis. The aim of our study was to select, analyze, and systematically review the recent scientific literature on the diagnostic value of CMR T1 and T2 parametric mapping in clinically suspected acute myocarditis. Materials and Methods: The literature search was performed in the PubMed database. Articles published in the years 2014-2024 were included in the analysis. At the initial stage, 458 articles were reviewed, and 13 exploratory research studies were further analyzed and presented in this systematic literature review. Results: The analysis included 686 patients with clinically suspected myocarditis and 372 subjects in the control group. The average age of patients with suspected myocarditis was 40.25 years; 26% of them were women. Prolonged native myocardial T1 relaxation time provides diagnostic accuracy in the setting of suspected acute myocarditis ranging from 69 to 99%, with sensitivity from 64 to 98% and specificity from 87 to 100%. Diagnostic accuracy of prolonged T2 relaxation time ranges from 47 to 87%, with sensitivity being from 48% to 94% and specificity from 60% to 92%. ECV alone showed moderate diagnostic performance, with diagnostic accuracy ranging from 62% to 76%, sensitivity from 47% to 73%, and specificity from 76% to 90%. T1 and T2 mapping and ECV, combined with the late gadolinium enhancement (LGE) technique, increases the probability of detecting myocardial inflammatory changes at various stages of the disease, improving the diagnostic accuracy to 96%. Conclusions: New quantitative CMR techniques, i.e., T1 and T2 mapping, have an advantage over conventional CMR sequences in detecting inflammatory myocardial structural changes and play an important role in diagnosing acute myocarditis. Incorporating these sequences in daily clinical practice increases the diagnostic value of CMR in acute myocarditis and becomes an alternative to endomyocardial biopsy, which has been considered the gold standard until now.
PCT No. PCT/EP94/02485 Sec. 371 Date Feb. 6, 1996 Sec. 102(e) Date Feb. 6, 1996 PCT Filed Jul. 28, 1994 PCT Pub. No. WO95/15329 PCT Pub. Date Jun. 8, 1995An apparatus for simulating the effect of a living organism on the change in shape, the disintegration and dissolution behaviour and the active-ingredient release of a pharmaceutical dosage form, including a beaker-shaped container for accommodating a test medium and the pharmaceutical dosage form and an agitating device for agitating the test medium, which agitating device can be moved periodically in a reciprocating movement into and back out of the container, wherein the agitating device includes a piston-shaped head portion arranged on a piston rod, which head portion is provided with through-openings for the test medium and the distance of the piston-shaped head portion from the container floor can be altered periodically in accordance with the periodic reciprocating movement of the agitating device, wherein, the piston rod is suspended from a gallows-shaped boom or the piston rod passes through a bore in the gallows-shaped boom in such a manner that downward movement of the piston-shaped head portion arranged on the piston rod is caused by gravity alone and wherein there is arranged in the container an intermediate base supported on the container floor, the base being provided with through-openings for the test medium and serving as a support for the dosage form, wherein the distance between the intermediate base and the container floor is adjustable by a device for adjusting the distance between the base and the floor.
Compositions for cleansing are disclosed that are not irritating to human skin. A composition is disclosed that includes at least 2 % of a mixture of a salt of an alkyl sulfoacetate and a salt of an ethoxylated alkyl sulfosuccinate, at least 3 % of a salt of an ethoxylated alkyl sulfate, at least 1 % of an amphoteric surfactant, at least 0.05 % of an alkyl glucoside, and at least 0.005 % of a phospholipid. A composition for cleansing is disclosed that includes about 2 % to 70 % of a mixture of a salt of an alkyl sulfoacetate and a salt of an ethoxylated alkyl sulfosuccinate, about 3 % to 40 % of a salt of an ethoxylated alkyl sulfate, about 1 % to 40 % of an amphoteric surfactant, about 0.05 % to 10 % of an alkyl glucoside, and about 0.005 % to 10 % of a phospholipid. A cleansing composition is further disclosed that includes about 41 % of a mixture of alkyl sulfoacetate and ethoxylated alkyl sulfosuccinate, about 34 % of an ethoxylated alkyl sulfate, about 22 % of an amphoteric surfactant, about 2 % of an alkyl glucoside, and about 0.5 % of a phospholipid. A composition for cleansing is also described which includes about 2 % to 50 % of a mixture of a salt of a sodium lauryl sulfoacetate and Disodium Laureth Sulfosuccinate, about 3 % to 35 % of Ammonium Laureth Sulfate, about 1 % to 30 % of Cocamidopropyl Betaine, about 0.05 % to 8 % of Coco-Glucoside and Coconut Oil, and about 0.005 % to 5 % of a phospholipid. A method of cleaning is also described, which includes contacting a surface to be cleansed with the composition of the invention. The composition can be used in a variety of personal care or household cleansers, such as contact lens care products, shampoos, soaps, body washes, mouthwashes, toothpastes, oral rinses, facial and wound cleansers, eye makeup removers, laundry and dishwashing detergents, and others.
The subject invention concerns non-degradable three dimensional porous co llagen scaffolds and coatings. These scaffolds can be prepared around sensor s for implantation into a body. A specific embodiment of the invention conce rns implantable glucose sensors. Sensors comprising a collagen scaffold of t he invention have improved biocompatibility by minimizing tissue reactions w hile stimulating angiogenesis. The subject invention also concerns methods f or preparing collagen scaffolds of the invention. The subject invention also concerns sensors that have a collagen scaffold of the invention around the exterior of the sensor.
The study aims were to: 1) evaluate the implementation of the B2B program to inform ongoing program modifications and facilitate future dissemination efforts, 2) assess whether the B2B program increases mental health and substance use treatment initiation and treatment retention among returning National Guard soldiers, and 3) explore whether the B2B program improves mental health symptoms, deceases hazardous alcohol use, and improves soldier well-being.

The study had three components which addressed each of the three specific aims. The first component assessed B2B implementation using an embedded mixed methods design. This evaluation included real-time assessment and adaptation of the program, as well as retrospective evaluation of implementation process, sustainability, and potential for spread. The second component addressed the impact of B2B on treatment initiation and retention. Preliminary analyses were completed using regression analyses. Pending additional data from the DoD, an interrupted time series design to assess Michigan National Guard soldiers' VA and non-VA services use in multiple time periods before and after the date of B2B implementation will be conducted.. The third study component assessed the impact of B2B on MI ARNG soldiers' outcomes using longitudinal survey data and adjusting for baseline mental health status using data from the Post Deployment Health Assessment (PDHA).